Full-Time

Healthcare Professional Marketing Manager

Posted on 10/31/2025

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$135k - $165k/yr

+ Variable incentive plan

United States

Hybrid

US Citizenship Required

Category
Growth & Marketing (6)
, , , , ,
Required Skills
Adobe Creative Suite
Branding/Brand Strategy
Canva
Marketing
Video Editing
Requirements
  • 8+ years of experience in commercial marketing, preferably in medical devices, healthcare, or life sciences. 6+ years with an advanced degree.
  • Strong experience in sales enablement, content development, and campaign execution.
  • Strong understanding of collaborating with sales, product, and clinical teams
  • Ability to translate clinical and technical information into customer-friendly messaging.
  • Strong attention to detail
  • Proficiency in design tools (e.g., Adobe Creative Suite, Canva) and basic video editing software.
  • Excellent project management, communication, and organizational skills.
  • Comfortable working independently and managing multiple priorities.
  • Education: Equivalent work experience or Bachelor’s degree in marketing, business administration, or a related field
  • Analytical mindset with proficiency in KPI tracking.
  • Experience working in a start-up or high-growth environment
  • Knowledge of regulatory requirements and compliance standards for medical devices.
  • Work location: In-office, hybrid, or remote
  • Travel: 30% travel
  • Full-time employment
  • Compliance with relevant county, state, and Federal rules regarding vaccinations.
Responsibilities
  • Oversee the creation and optimization of sales tools, presentations, and collateral tailored to various customer segments and sales stages.
  • Collaborate with Sales leadership to identify gaps and opportunities in training and messaging resources.
  • Ensure alignment of sales materials with brand strategy and product positioning.
  • Collaborate with sales training to manage a sales enablement content calendar to ensure the timely and consistent rollout of relevant collateral, messaging updates, and training resources.
  • Lead the development of key HCP marketing campaigns, including messaging, content strategy, and sales collaterals (e.g., brochures, sell sheets, case studies, product presentations)
  • Translate clinical data and technical product information into impactful marketing narratives and tools.
  • Partner with Marcom and external agencies to manage campaign calendars, workflows, and creative execution strategy.
  • Guide the development of visual assets including infographics, presentations, and product visuals that reflect a consistent brand identity.
  • Manage basic video production and editing for training, testimonials, and product demonstrations.
  • Liaise with design vendors and agencies to ensure timely delivery and quality of creative assets.
  • Collaborate with Sales, Product Marketing, and Clinical teams to ensure marketing efforts are aligned with business goals.
  • Support the execution of clinical and competitive marketing tactics that support product adoption.
  • Stay informed on industry trends and competitor activity to help inform messaging and content development.

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Calyxo raised $40 million in Series F from specialist healthcare investors.
  • CVAC crossed 40,000 kidney stone procedures, strengthening physician referenceability.
  • Funding supports commercial expansion and health-economic evidence generation.

What critics are saying

  • Boston Scientific already owns installed ureteroscopy franchises in most hospitals.
  • A 2024 MAUDE report documented sepsis and death after CVAC use.
  • Calyxo still depends on early evidence; larger studies can narrow differentiation.

What makes Calyxo unique

  • CVAC continuously aspirates stone fragments during and after laser lithotripsy.
  • FDA cleared CVAC in March 2024, lowering regulatory friction.
  • ASPIRE showed superior stone clearance and lower residual stone volume versus URS.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.

INACTIVE